Display options
Cite
Yamamoto D, Tsubota Y, Utsunomiya T, et al. Osteonecrosis of the jaw associated with everolimus: A case report. Mol Clin Oncol. 2016;6(2):255-257doi: 10.3892/mco.2016.1100.
Yamamoto, D., Tsubota, Y., Utsunomiya, T., Sueoka, N., Ueda, A., Endo, K., Yoshikawa, K., & Kon, M. (2017). Osteonecrosis of the jaw associated with everolimus: A case report. Molecular and clinical oncology, 6(2), 255-257. https://doi.org/10.3892/mco.2016.1100
Yamamoto, Daigo, et al. "Osteonecrosis of the jaw associated with everolimus: A case report." Molecular and clinical oncology vol. 6,2 (2017): 255-257. doi: https://doi.org/10.3892/mco.2016.1100
Yamamoto D, Tsubota Y, Utsunomiya T, Sueoka N, Ueda A, Endo K, Yoshikawa K, Kon M. Osteonecrosis of the jaw associated with everolimus: A case report. Mol Clin Oncol. 2017 Feb;6(2):255-257. doi: 10.3892/mco.2016.1100. Epub 2016 Dec 05. PMID: 28357105; PMCID: PMC5351763.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2017 Feb;6(2):255-257. doi: 10.3892/mco.2016.1100. Epub 2016 Dec 05.

Osteonecrosis of the jaw associated with everolimus: A case report.

Molecular and clinical oncology

Daigo Yamamoto, Yu Tsubota, Toshiki Utsunomiya, Noriko Sueoka, Aiko Ueda, Kayoko Endo, Katsuhiro Yoshikawa, Masanori Kon

Affiliations

  1. Department of Surgery, Kansai Medical University Medical Center, Moriguchi, Osaka 570-8507, Japan.
  2. Department of Otorhinology, Kansai Medical University Medical Center, Moriguchi, Osaka 570-8507, Japan.
  3. Department of Surgery, Kansai Medical University Medical Center, Moriguchi, Osaka 570-8507, Japan; Department of Surgery, Kansai Medical University-Affiliated to Hirakata Hospital, Hirakata, Osaka 573-1191, Japan.

PMID: 28357105 PMCID: PMC5351763 DOI: 10.3892/mco.2016.1100

Abstract

Everolimus, a mammalian target of rapamycin inhibitor, has recently been approved for the treatment of metastatic estrogen receptor-positive breast cancer, at a daily dose of 10 mg in combination with exemestane. Osteonecrosis of the jaw (ONJ) is a rare but severe condition, characterized by exposed necrotic bone, and is associated with various drugs that are often used to treat advanced malignancies. We herein report the case of a patient with breast cancer who developed ONJ during treatment with everolimus, which improved after discontinuation of the drug. To the best of our knowledge, this is the first reported case of everolimus-associated ONJ in a patient receiving everolimus for metastatic breast cancer. In 2014, an 80-year-old woman was started on treatment with everolimus and exemestane for stage IIB estrogen receptor-positive breast cancer. Within 2 months, the left side of her face became edematous, with localized heat and tenderness of the left mandibular region and a 3-mm round area of exposed bone. There was purulent discharge and the surrounding gingiva was edematous and erythematous. The left mandible exhibited a low signal intensity area on T1-weighted magnetic resonance imaging. Treatment was discontinued and ONJ showed improvement after 2 months. Therefore, when prescribing everolimus for metastatic breast cancer, oncologists should be aware of the possibility of ONJ as a complication.

Keywords: breast cancer; everolimus; osteonecrosis of the jaw

References

  1. Breast Cancer Res Treat. 2010 Jul;122(1):181-8 - PubMed
  2. J Natl Cancer Inst. 2015 Aug 06;107(10 ):null - PubMed
  3. Ann Stomatol (Roma). 2013 Oct 24;4(Suppl 2):20-1 - PubMed
  4. J Can Dent Assoc. 2012;78:c85 - PubMed
  5. Adv Exp Med Biol. 2007;608:1-22 - PubMed
  6. Clin Cancer Res. 2009 Mar 1;15(5):1612-22 - PubMed
  7. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Mar;113(3):e1-3 - PubMed
  8. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Jun;115(6):e32-6 - PubMed
  9. Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S149-61 - PubMed
  10. Br J Oral Maxillofac Surg. 2013 Dec;51(8):e302-4 - PubMed
  11. Clin Cases Miner Bone Metab. 2013 May;10(2):139-41 - PubMed
  12. Oncology. 2009;76(3):209-11 - PubMed
  13. Acta Haematol. 2010;124(2):79-85 - PubMed
  14. Curr Opin Support Palliat Care. 2010 Sep;4(3):200-6 - PubMed
  15. Bone. 2004 Nov;35(5):1144-56 - PubMed
  16. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Feb;115(2):192-200 - PubMed
  17. Ann Surg. 2002 Sep;236(3):295-302; discussion 302-3 - PubMed
  18. J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7 - PubMed

Publication Types